Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: HIV-1 Tat, an enhancer of virus infectivity and disease promoter: target for preventive and therapeutic interventions.

Frontiers in immunology·2026
Same author

Broad-spectrum CRISPR-Cas13d-mediated strategy for combating human coronaviruses.

Molecular therapy. Nucleic acids·2026
Same author

Elucidating the kinetics of CRISPR-SaCas9 action to obtain effective HIV DNA excision with two gRNAs.

Nucleic acids research·2026
Same author

The genetic architecture of HIV-1 virulence.

Virus evolution·2025
Same author

HIV-2 evades restriction by ZAP through adaptations in the U3 LTR region despite increased CpG levels.

Nucleic acids research·2025
Same author

HIV-phyloTSI: subtype-independent estimation of time since HIV-1 infection for cross-sectional measures of population incidence using deep sequence data.

BMC bioinformatics·2025

Related Experiment Video

Updated: Jun 19, 2026

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
09:27

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

Published on: May 30, 2013

Towards a genetic AIDS vaccine.

Antonia V Bordería1, Ben Berkhout

  • 1Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infectious Diseases and Immunology Amsterdam, Academic Medical Center, University of Amsterdam, the Netherlands. antonio.borderia@gmail.com

Retrovirology
|October 20, 2009
PubMed
Summary

Gene therapy created an effective HIV-1 vaccine in monkeys. The treatment produced an immunoadhesin that neutralized the virus, offering long-term protection against simian-immunodeficiency virus (SIV) infection.

More Related Videos

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing
10:18

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing

Published on: October 16, 2018

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Related Experiment Videos

Last Updated: Jun 19, 2026

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
09:27

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

Published on: May 30, 2013

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing
10:18

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing

Published on: October 16, 2018

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Area of Science:

  • Immunology
  • Gene Therapy
  • Vaccinology

Background:

  • Developing an effective vaccine against human immunodeficiency virus (HIV) remains a significant global health challenge.
  • Previous vaccine strategies have faced limitations in inducing durable protective immunity.

Purpose of the Study:

  • To assess the efficacy of a novel gene therapy approach for HIV-1 vaccine development.
  • To determine if vector-mediated gene transfer can elicit long-lived neutralizing activity and protection against simian-immunodeficiency virus (SIV) infection in non-human primates.

Main Methods:

  • Utilized vector-mediated gene transfer to introduce a gene encoding an antibody-like immunoadhesin.
  • Administered the gene therapy to monkeys to assess its ability to produce neutralizing agents in the bloodstream.
  • Challenged the treated monkeys with SIV to evaluate vaccine-induced protection.

Main Results:

  • The gene therapy successfully produced a persistent, antibody-like immunoadhesin in the blood of the treated monkeys.
  • This immunoadhesin demonstrated potent neutralizing activity against the virus.
  • Monkeys receiving the gene therapy exhibited significant protection against SIV infection.

Conclusions:

  • Vector-mediated gene transfer is a promising strategy for developing effective HIV-1 vaccines.
  • The induction of long-lived neutralizing antibodies via gene therapy can confer protection against viral infection.
  • This approach represents a potential breakthrough in vaccine development for lentiviruses.